The U.S. Food and Drug Administration approved a new weight-loss pill developed by Eli Lilly on Wednesday.
Known as orforglipron, or under the brand name Foundayo, the once-daily tablet is the second GLP-1 drug in pill form to receive FDA approval. It follows Novo Nordisk’s Wegovy pill, which was approved in December.
The approval sets up a competition between Eli Lilly and Novo Nordisk for the growing market of Americans seeking effective weight-loss medications. Foundayo will directly compete with the pill version of Wegovy.
This marks the second obesity pill to gain FDA approval, ratcheting up pressure on Novo Nordisk and opening a new front in the booming weight-loss drug market.